

Factors Influencing Transepidermal Water Loss Measurements Used to FDA U.S. FOOD & DRUG **Test Skin Barrier Integrity In Vitro: A Literature Review**

¹Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA ²Thomas Wootton High School, Rockville, MD, USA

Transepidermal water loss (TEWL) measurements are used to distinguish competent (intact) vs. compromised skin sections for in vitro permeation testing (IVPT). The measurements are expected to be done with skin sections mounted on diffusion cells, where the underside of the skin is in contact with the receptor solution. In this context of use, the TEWL measurement probes may need specialized designs or adaptors to optimize the probe interface with the skin area being monitored. The current literature review aimed to delineate factors that could influence TEWL measurements for in vitro skin barrier integrity testing.



Ying Jiang¹, Matteo A. Simamora², Tannaz Ramezanli¹, Sam G. Raney¹

Introduction

Figure 2. Representative adaptations (by manufacturers) of TEWL measurement devices for in vitro use

ADMINISTRATION

Open chamber



Picture courtesy of Courage+Khazaka electronic GmbH

Closed chamber



Picture courtesy of Delfin technologies

Closed condenser chamber



Picture courtesy of Biox Systems Ltd



Literature in the PubMed database related to TEWL measurement (published in November 2020, or before) were retrieved (based on key terms including TEWL, transdermal) epidermal water loss, trans-epidermal water loss, transepidermal water loss) and screened to select those involving a relevant technique/device used for in vitro studies with excised human skin. From the individual studies, method parameters and measured values were summarized and compared. Information on relevant device manufacturers' websites were also reviewed for commercially available TEWL measurement device.

It was apparent that TEWL skin barrier integrity test results reported may have been influenced by factors related to ambient conditions, devices, diffusion cells, skin sections, and the placement of the device. Independently, the relevant method parameters in individual studies were found to be variable and/or not sufficiently well described, which may explain some of the differences in the reported TEWL values (baseline ranging from <1 g/m²/hr), even when the same TEWL measurement device was used. In particular, it was not always clear whether or not the TEWL was measured under conditions where the skin surface temperature was at 32°C ± 1°C (to align with that in vivo). Additionally, differences in diameters and/or interface geometries between TEWL measurement devices and skin/donor compartments were often not reported in detail, and unreported factors could have contributed to differences in TEWL measurements.

Table 1. Factors Influencing TEWL Measurements That Are Used to Test Skin Barrier Integrity In Vitro

	Ambient condition	Device	Diffusion cells	Skin sections	Placement of the device
Factors influencing the production of TEWL	 Ambient air temperature Relative humidity Light source 	 Operational mechanism Impact on the microclimate above the skin surface 	 Receptor solution temperature Impact on the skin surface temperature 	 Skin surface temperature Skin source, type, preparation Skin equilibration 	
Factors influencing the measurement of TEWL	 Ambient air movements and turbulence 	 Operational mechanism Susceptibility to the influence of the ambient conditions Probe temperature Calibration Probe aging Use of in vitro adapters 	 Consistency of the height of the donor compartment Impact on the distance between the probe and the skin surface 		 Alignment of the diameters of the probe orifice and the skin area being measured (in certain circumstances) Consistency of the geometry of measurement

Factors Influencing Transepidermal Water Loss Measurements Used to FDA U.S. FOOD & DRUG **Test Skin Barrier Integrity In Vitro: A Literature Review**

Methods

Results



Factors Influencing Transepidermal Water Loss Measurements Used to Test Skin Barrier Integrity In Vitro: A Literature Review

Table 2. Summary of Key Method Parameters from Individual Studies

Operational Mechanism	Ambient temperature and humidity	Receptor tempe
Open chamber (16 studies)	 9 did not report (Brugués et al., Cristiano et al., Betz et al., D'Angelo Costa et al., Elkeeb et al., Parra et al., Dabboue et al., Osman-Ponchet et al., Suñer-Carbó et al.) 5 reported in ranges of 18-28°C, 25-50% (Chilcott et al., Garcia et al., Kopečná et al., 2017a, Kopečná et al., 2017b, Kopečná et al., 2019) 1 reported room temperature, controlled humidity (Verbaan et al.) 1 reported 32±1°C, 40-60% (Heylings et al.) 	 3 did not real., Verbaan et al., Verbaan et al., E 8 reported al., E 8 reported al., Parra et al., F (Incubator), D'Ange Kopečná et al., 2018 Kopečná et al., 2018 1 reported al., 2018 1 reported al., et al., Garcia et al., Ponchet et al.)
Closed chamber (9 studies)	 6 did not report temperature and 8 did not report relative humidity (Elkeeb et al., Guth et al., Manda et al., Jacques-Jamin et al., Hopf et al., Nguyen & Banga, Zhang et al.(temperature reported), Badran et al.(temperature reported)) 2 reported ~25°C or room temperature (Badran et al., Zhang et al.) 1 reported 24±2°C, 30±10% (Atrux- Tallau et al.) 	 2 did not re Jacques-Jamin et al 3 reported al., Badran et al., He 1 reported al.) 3 reported Tallau et al., Manda Banga)
Closed condenser chamber (3 studies)	 2 did not report (Gomaa et al., Elkeeb et al.) 1 reported ~24°C, 40–50% (Hui et al.) 	 2 did not re Hui et al.) 1 reported 3 (Gomaa et al.)

Based on inferences we drew from our review of the literature, we have identified and summarized factors that reportedly have the potential to influence the results of a TEWL skin barrier integrity test, and considered the implications of (not) controlling these factors in the method parameters used for individual studies in the literature. Given that there are many potential factors that can influence TEWL measurements, suitable acceptance criteria in individual studies may depend somewhat on the specific devices, method parameters, and skin that are used in a study.

This project was supported in part by an appointment (Ying Jiang) to the Research Participation Program at the FDA Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and FDA. The views expressed in this poster are those of the authors and should not be construed to represent FDA's views or policies.

<u>Results</u>

solution rature	Skin surface temperature	Alignment of the device in re compartment and/or the
port (Cristiano et Elkeeb et al.) ~32°C (Brugués leylings et al. 0 Costa et al., 9, Suñer-Carbó et al., 7a, Kopečná et al., 35°C (Chilcott et ~37°C (Dabboue Betz et al., Osman-	 10 did not report (Brugués et al., 2015, Cristiano et al., 2020, Verbaan et al., 2007, D'Angelo Costa et al., 2018, Parra et al., Osman-Ponchet et al., 2017, Kopečná et al., 2019, Kopečná et al., 2017, Kopečná et al., 2019, Suñer-Carbó et al., 2019, Kopečná et al., 2017b) 6 reported ~32°C (Garcia et al., Heylings et al. (Incubator), Chilcott et al., Betz et al., Elkeeb et al., Dabboue et al. (measured)) 	 6 did not report (Brugués et al., Osman-Ponchal., Betz et al., Kopečná et al., 2017b) 3 reported probe placed on skin (Parra et al.) 1 reported probe placed on top o (Dabboue et al.) 1 reported probe (specialized for skin (Cristiano et al.)) 5 reported probe placed on an ine (Garcia et al., Chilcott et al., Elkeeb et al., Kopečná et al.)
port (Elkeeb et al., I.) ~32°C (Guth et opf et al.) ~34°C (Zhang et ~37°C (Atrux- et al., Nguyen &	 5 did not report (Guth et al., Manda et al., Badran et al., Jacques-Jamin et al., Hopf et al.) 4 reported ~32°C (Atrux-Tallau et al., Zhang et al., Elkeeb et al., Nguyen & Banga) 	 3 did not report (Jacques-Jamin et al., Hopf et 1 reported probe placed on skin (3 reported probe placed on top o (Atrux-Tallau et al., Zhang et al., Guth et al.) 1 reported probe placed on top o with manufacturer's in vitro adapt 2 reported probe placed on an information (Elkeeb et al., Badran et al.)
port (Elkeeb et al., 37±0.5°C	 1 did not report (Gomaa et al.) 2 reported 32°C (Elkeeb et al., Hui et al.) 	 1 reported probe placed on top of with manufacturer's in vitro adapt 2 reported probe placed on an integration of the state of the state.

Conclusions

Acknowledgement and Disclaimer

FDA U.S. FOOD & DRUG

References

Alexander et al. J Invest Dermatol. 2018;138(11):2295-

Badran et al. Eur J Pharm Med Res. 2009;36(4-5):511-

Chilcott et al. J Invest Dermatol. 2002;118(5):871-875

Betz et al. Int J Pharm. 2001;228(1-2):147-59

Brugués et al. Nanomedicine. 2015;10(2):227-40

Atrux-Tallau et al. Arch Dermatol Res.

Cristiano et al. J Pharm Biomed Anal.

Dabboue et al. Biomed Res Int. 2015

D'Angelo Costa et al. AAPS PharmSciTech.

Elkeeb et al. Skin Res Technol, 2010;16(1):9-15

Gomaa et al. Toxicol In Vitro. 2010;24(7):1971-8

Heylings et al. Toxicol In Vitro. 2001;15(4-5):597-600

Garcia et al. Int J Cosmet Sci. 2002;24:25-34

Guth et al. Toxicol In Vitro. 2015;29(1):113-23

Hui et al. Skin Res Technol. 2011;18(1):108-13

Imhof et al. Int J Cosmet Sci. 2009;31(2):97-118

Hopf et al. Toxicol Lett. 2013;224(1):47-53

2007;299(10):507-11

2020;15;186:113295

2018;19(5):2418-25

300

23

lation to the donor skin section

het et al., Suñer-Carbó et al., Verbaan et

(Heylings et al., D'Angelo Costa et al.,

f donor compartment

in vitro use) placed on

-house made adapter , 2019, Kopečná et al., 2017a)

al., Nguyen & Banga)

(Zhang et al.)

f donor compartment

f donor compartment

ter (Manda et al.)

-house made adapter

of donor compartment ter (Gomaa et al.) house made adapter Jacques-Jamin et al. Skin Pharmacol Physiol. 2017;30(2):55-65 Kopečná et al. Pharm Res. 2017a;34(3):640-653 Kopečná et al. Pharm Res. 2017b;34(10):2097-2108 Kopečná et al. Sci Rep. 2019;9(1):1-12 Manda et al. J Pharm Sci. 2014;103(6):1638-42 Nguyen and Banga. Pharmaceutics. 2018;10(3):117 Osman-Ponchet et al. Dermatol Ther. 2017;7(3):407-15 Parra et al. Int J Pharm. 2016;501(1-2):10-17 Suñer-Carbó et al. Int J Pharm. 2019;11(2):66

Verbaan et al. J Control Release. 2007;117(2):238-245 Zhang et al. J Control Release. 2018;51:129-35